This week

semax got legal access while selank is still waiting — comments close this friday

On October 28, HHS issued an interim enforcement discretion policy clearing six peptides for licensed 503A compounding pharmacies while formal FDA rulemaking continues. [NPR reported the announcement on October 28](https://www.wunc.org/2026-10-28/trump-administration-will-allow-pharmacies-to-make-popular-peptides), and the coverage focused on what made the list. [The policy itself](https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy.pdf) names BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500 — with public comments due November 13, this Friday. Selank was not among the six. That absence is the story of the week in nootropic circles. Semax, Selank's closest pharmacological cousin — the two peptides were developed by the same Russian institute, share a neuroactive profile, and have been stacked together in optimization protocols for the better part of a decade — just received a legal compounding path. Selank is still waiting for its own FDA advisory committee review, expected at a second panel meeting no earlier than February 2027. The two peptides are discussed together so often that one is frequently mistaken for the other. For people following this corner of the regulatory story, the question this week is not what Selank is — it is why its twin got cleared first.

The molecule

selank is a heptapeptide tuftsin analog designed around enkephalin and bdnf signaling

Selank is a seven-amino-acid synthetic peptide derived from tuftsin, a naturally occurring tetrapeptide fragment of immunoglobulin G with known activity in immune signaling. The modification — appending three additional amino acids — was designed to stabilize the structure, extend the half-life beyond tuftsin's very short in vivo residence, and preserve or enhance the biological activity. The core mechanistic hypothesis is that Selank interacts with enkephalin-degrading enzymes, reducing the breakdown of endogenous opioid peptides involved in anxiety modulation. Additional work has pointed to BDNF upregulation and effects on serotoninergic and dopaminergic transmission, based on animal studies and cell-based models. Selank was developed by the Institute of Molecular Genetics of the Russian Academy of Sciences — the same institution that produced Semax — and has been registered as an anxiolytic drug in Russia since 2009. That regulatory history matters for the evidence conversation: Russia's approval was based on clinical trial data conducted in Russian research settings, and those studies form the backbone of what most Western sources cite. [PubMed's Selank literature](https://pubmed.ncbi.nlm.nih.gov/?term=Selank) shows the full research footprint, heavily weighted toward Russian-language publications and a narrower English-language base.

The pitch

online it's the anxiolytic half of the semax-selank stack — calm without sedation

In the nootropic and optimization community, the Selank pitch is specific: it is the anxiolytic half of the Semax-Selank stack, delivering calm and anxiety reduction while Semax carries the cognitive and focus claims. The appeal is that Selank reportedly does this without the sedation profile of benzodiazepines or the dependence risks that accompany most pharmaceutical anxiolytics. The language in circulation — 'anxiety off a cliff,' 'GABA without the fog,' 'Russia's answer to benzos' — has moved through biohacking forums since the mid-2010s, amplified by an international userbase importing it from Eastern European suppliers or accessing it through optimization clinics. Searches for Selank are up 31% this month, partly driven by the HHS policy that cleared Semax and left Selank out. The compound sits in a distinctive position: approved by one major national regulator for one of the same uses being marketed online, unreviewed by the FDA, and not yet scheduled for a US advisory committee hearing. The nootropic community has been using Selank for years. The regulatory process is now catching up — just not to Selank yet.

What the data says

small russian rcts show anxiolytic signal — independent western replication is the gap

The human evidence record for Selank is real and limited. Russian randomized controlled trials conducted between the 1990s and 2010s found anxiolytic effects in patients with generalized anxiety disorder and neurasthenia, with cited trials showing symptom reduction versus placebo on standardized anxiety rating scales — the data package that supported Russia's 2009 approval. The recognized limitation in Western review is not that the studies are unreliable in design but that they emerged from a small network of Russian research institutions, without independent replication outside that infrastructure, and published in journals that do not consistently meet Western reporting standards. The FDA advisory committee process — which will evaluate Selank when it reaches that meeting, expected sometime in 2027 — will apply the same scrutiny it applied to Semax, which passed the July 2026 vote, and to emideltide, which the July panel voted against. [ClinicalTrials.gov's Selank registry](https://clinicaltrials.gov/search?term=Selank) documents the registered trial footprint, which is limited outside Russian research infrastructure. The anxiolytic signal in the literature is consistent across the Russian trial record. The question for the FDA process is whether that data package meets the standards required for 503A bulks list consideration.

Early human — PeptideFactCheck stance

the russian approval and small rct record hold the tier — the fda review is 2027's chapter

Selank holds PeptideFactCheck's Early human evidence tier: interesting enough to watch, too early for broad certainty. That tier reflects what the record actually contains — a real pharmacological rationale built on tuftsin biology and enkephalin regulation, a Russian drug approval based on clinical trial data, and a human literature base that exists but has not been independently replicated with the institutional diversity Western reviewers consider a standard floor. The October 28 HHS enforcement discretion that cleared Semax is not the right frame for Selank today — that policy addressed six specific peptides and Selank was not among them. The November 13 comment period closing this Friday is about public input on those six, not a vote on Selank's status. The FDA advisory committee review expected in early 2027 is where the US regulatory story will begin in earnest. In the meantime, [the HHS enforcement discretion](https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy.pdf) creates an operational asymmetry inside any clinic running Semax-Selank stacks: Semax now has a legally sanctioned compounding path under defined conditions, and Selank does not. The tier is a receipt. Source trail before certainty.

Editorial boundary

What this page will not do

It will not provide dosing, cycling, sourcing, injection, or personal medical instructions. The job is to classify claims and explain mechanisms.